Gene-based blood test for melanoma may catch early signs of cancer’s return

Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the study showed that approximately 80% of stage III melanoma patients who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence.

The researchers also found that the disease returned more than four…